CN103288698A - Novel method for synthetizing prostaglandin analogue - Google Patents

Novel method for synthetizing prostaglandin analogue Download PDF

Info

Publication number
CN103288698A
CN103288698A CN2013101650750A CN201310165075A CN103288698A CN 103288698 A CN103288698 A CN 103288698A CN 2013101650750 A CN2013101650750 A CN 2013101650750A CN 201310165075 A CN201310165075 A CN 201310165075A CN 103288698 A CN103288698 A CN 103288698A
Authority
CN
China
Prior art keywords
carbon
formula
reaction
keys
degree
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013101650750A
Other languages
Chinese (zh)
Inventor
杨波
庞智斌
崔柏林
李延华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOUSTON INTERNATIONAL (BEIJING) Inc
Original Assignee
LOUSTON INTERNATIONAL (BEIJING) Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOUSTON INTERNATIONAL (BEIJING) Inc filed Critical LOUSTON INTERNATIONAL (BEIJING) Inc
Priority to CN2013101650750A priority Critical patent/CN103288698A/en
Publication of CN103288698A publication Critical patent/CN103288698A/en
Pending legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention relates to a novel method for synthetizing prostaglandin analogues, and an important intermediate compound related to the novel method. The method comprises the steps of (a), just protecting 15-site hydroxyl of the compound of a formula 2 by utilizing a hydroxyl protection group under an alkaline condition; (b) restoring a lactone ketone group from DIBAL (diisobutylaluminium hydride) to obtain the intermediate of a formula 4; (c) carrying out Wittig reaction on the intermediate of the formula 4 by utilizing 4-carboxy butyl-triphenylphosphine bromide, carrying out esterification or amidation after connecting an alpha chain; (d) removing 15-site hydroxyl protection group to obtain the prostaglandin analogue of the formula 1. The method is less in side reaction, easy to monitor, and convenient to separate due to the fact that the difference between a crude product and the polarity of a process material is large.

Description

The novel method of the plain analogue in a kind of synthetic prostatitis
Technical field
The present invention relates to the novel method of the plain analogue in a kind of synthetic prostatitis, and the midbody compound that relates in the novel method.
Background technology
(prostaglandin is that one group of its chemical nature of important active substance that extensively is present in Mammals and human body is the unsaturated fatty acids of 20 carbon atoms of tool PG) to the prostatitis element.The basic framework that constitutes PG is the prostatitis alkanoic acid, a tool ring five alkane cores and two side chains.According to five-ring or whole molecular structure difference, prostaglandin(PG) can be divided into types such as A, B, C, D, E, F, G, H, I.Study more have E, F, A, B, I type (being PGE, PGF, PGA, PGB, PGI).And prostatitis plain class medicine PGF2 α thinks tool potentiality and the most effective local intraocular pressure lowering medicine at present, its reducing iop mainly is that the aqueous humor drainage of the trabecular network approach non-classical by improving uveal tract sclera approach realizes, it has good reducing iop at night simultaneously, can reduce intraocular pressure fluctuation round the clock, alleviate the intraocular pressure fluctuation to the infringement of the visual field and optic nerve.Represent the class medicine comprise latanoprost (Latanoprost, Xalatan), travoprost (Travoprost) and bimatoprost (Bimatoprost).At present this 3 kinds of prostatitis elements synthetic mainly contains following two lines:
Route 1.
Figure BDA00003152887600011
R 1And R 2Be hydrogen (EP2143712) or suitable hydroxy-protective group; as THP (WO2005058812); TBS (WO210109476); TMS (WO2003074481) etc. raw material is through the DIBAL reduction; the Wittig reaction, esterification or amidation and corresponding protection and deprotection steps obtain the plain analogue in prostatitis.
Route 2.
Connect the ω chain by the Michael addition, be converted to the plain analogue in prostatitis through 9 carbonyl reductions and corresponding functional group again.
Because there is selective problems in route 29 related carbonyl reductions, so if synthetic methods that adopt routes 1 of a lot of prostatitis element more. when 11,15 hydroxyls are not done protection and caused the Wittig reaction 5, the ratio of 6-trans-isomer(ide) increases.And adopting traditional protecting group when adopting acetal such as THP or ketal class protecting group, deprotection generally uses acidic conditions, might cause the dehydration of 15 hydroxyls, produces a lot of by products, and then causes yield to reduce, and product separates very difficult.Using silicon ethers protecting group is reasonable selection, yet under general silicon ether protecting group, 11 reaction site may partly migrate to 9 under the Wittig reaction conditions, has increased the complexity of reaction, and has produced many by products that are difficult to separate.In addition, the by product diphenyl phosphine oxy pentanoic acid that the Wittig reaction produces makes it very difficult with separating of product owing to its physical properties.
Summary of the invention
At the above problem that prior art exists, the plain analogue in the synthetic prostatitis of the route below the present invention has used:
Figure BDA00003152887600021
? ? 13,14 X Z W
a Bimatoprost Two keys -CH2- -H -NHEt
b Latanoprost Singly-bound -CH2- -H -O-i-Pr
c Travoprost Two keys -O- -CF 3 -O-i-Pr
On the one hand, the invention provides the preparation method for the preparation of the plain analogue in formula 1 prostatitis, described method comprises:
(a) under alkaline condition, use hydroxyl protecting group, only 15 hydroxyls of formula 2 compounds are protected;
(b) DIBAL reduction lactone ketone group, acquisition formula 4 intermediates,
(c) use 4-carboxylic butyl-triphenylphosphine bromide and formula 4 intermediates to carry out the Wittig reaction, behind the connection α chain, esterification or amidation;
(d) slough 15-position hydroxyl protecting group, obtain the plain analogue in prostatitis of formula 1.
Formula 2 starting compounds be 2-oxa--3-oxo-6-suitable-(1-alkyl or alkoxyl group replace-3 ' Alpha-hydroxy-1 '-trans-butenyl)-7-is trans-phenoxy group-suitable-dicyclo also ［ 3.3.0 ］ octane be that known compound (is pressed Bioorg﹠amp; Med Chem12 (2004) 3451-3469 method is synthetic).
Preferably, be hydroxyl protecting group with tert-butyl diphenyl silicon ether (TBDPS), only 15 hydroxyls are protected, behind the connection α chain, do esterification or amidation earlier, slough silicon ether protecting group by tetrabutyl ammonium fluoride at last, obtain the prostatitis element.
Method of the present invention had both guaranteed the solvability of hemiacetal 4, again can be in nearly neutral environment the deprotection base, thereby avoided the side reaction of 15 hydroxyls.Introduce the uv-absorbing that tert-butyl diphenyl silicon ether has strengthened each intermediate in addition, be convenient to middle controlling/monitoring. and this silicon ether protecting group strengthened the hydrophobic nature of each intermediate, reduced the extraction times of last handling process.The crude product of Wittig reaction directly carries out the esterification of back, and the esterification products polarity of esterification products and diphenyl phosphine oxy pentanoic acid differs bigger, the convenient separation.
Can select alkane and various ethers, alkane, reagent such as aromatics for use with 15 hydroxyls of tert-butyl diphenyl silicon ether protection; such as methylene dichloride, THF, MCPE; DMF; toluene equal solvent, alkali can select for use various alkali such as imidazoles, triethylamine; pyridine; DMAP, DEA etc. temperature of reaction-10～60 degree, the reaction times was at 1～20 hour.
DIBAL reduction solvent can be selected ethers, THF, toluene, haloalkane etc. for use. and temperature of reaction-80～-10 degree, the reaction times was at 1～20 hour.
The Wittig reaction can be used systems such as DMSO/NaH, t-BuOK/THF, NaHMDS/THF.Temperature of reaction-50～50 degree. 1～20 hour reaction times.
Esterification can be used diazomethane, or methyl-sulfate, methylating reagent and DBU such as methyl iodide, and pyridine, triethylamine, DME etc. are rich, and use is united in sour agent.The i-PrI/DBU system is generally used in the isopropyl esterification. temperature of reaction-50～50 degree. and 1～20 hour reaction times.
Use pure ethamine or its water/alcoholic solution as the aminolysis step 1.Temperature of reaction-20～50 degree, 4 hours～4 days reaction times.
Deprotection steps is generally used tetrabutyl fluoride amine or hydrofluoric acid or other silicon ethers deprotecting regent.Solvent can be selected ethers for use, THF, ester class, haloalkane and aromatics etc. and temperature of reaction-10～70 degree, the reaction times was at 1～20 hour.
On the other hand, the present invention relates to the midbody compound that novel method is used, these intermediates comprise the compound of above-mentioned formula 3, formula 4 and formula 5, and the structure of these midbody compounds is significant to reducing the by product that generates in the target product process.
THP: tetrahydropyrans-2-base
TBS: tertiary butyl dimethyl is silica-based
DIBAL: diisobutylaluminium hydride
THF: tetrahydrofuran (THF)
MCPE: methylcyclopentyl ether
DMF: dimethyl formamide
The DMAP:4-Dimethylamino pyridine
DEA: diethylamine
MTBE: methyl tertiary butyl ether
DBU:1,8-diazabicylo [5.4.0] 11 carbon-7-alkene
TBAF: tetrabutyl ammonium fluoride
Embodiment
Embodiment 1
(3aR, 4R, 5R, 6aS)-((S, E)-3-(tert-butyl diphenyl silica)-5-benzene penta-1-alkene-1-yl)-2-oxo six hydrogen-2H-pentamethylene is [b] furans-5-yl benzoic acid ester (3a) also for 4-
Add 10 in the 1L there-necked flask and digest compound 2a, 90 milliliters of methylene dichloride, 5 gram imidazoles; 0.25 gram DMAP is cooled to the 0-10 degree under the nitrogen protection, drip the mixed solution of 10.1 gram TBDPSCl and 30 milliliters of methylene dichloride; added in about 10 minutes; the adularescent insolubles generates about the .20 degree and stirred 10 hours, TLC(Rf=0.9, and toluene: EtOAc3:2) detection reaction is complete; with salt washing 2 times; anhydrous sodium sulfate drying filters the solution that obtains compound 3a, is directly used in later reaction.
Get concentrate in a small amount the back silica gel column chromatography (eluent is methylene dichloride: normal hexane 1:1) obtain pure product.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.04(s,9H),1.81(m,2H),2.12(dd,1H),1.83-2.61(m,6H),2.74(m,1H),4.22(q,1H),4.92(m,1H),5.08(t,1H),5.26(dd,1H),5.56(dd,1H),6.98(d,2H),7.11-7.22(m,3H),7.31-7.43(m,8H),7.53(m,1H),7.63(m,4H),7.96(m,2H).
Embodiment 2
(3aR, 4R, 5R, 6aS)-((S, E)-3-(tert-butyl diphenyl silica)-5-benzene penta-1-alkene-1-yl) six hydrogen-2H-pentamethylene is [b] furans-2 also, 5-glycol (4a) for 4-
In the solution of embodiment 1, add 140 milliliters of methylene dichloride again; be cooled to-60 degree under the nitrogen protection; 130 milliliters of the DIBAL toluene solutions of dropping 25%; added in about 60 minutes. keep-60 degree and stirred 1.5 hours; slowly add 70 ml waters and destroy unnecessary DIBAL; remove by filter aluminium hydroxide, concentrated filtrate. residue is obtained compound 4a, 15.4g with silica gel column chromatography (methylene dichloride/methyl tertiary butyl ether 1:1).
1H-NMR(CDCl 3,300MHz)δ(ppm)1.05(s,9H),1.64-2.05(m,6H),2.10-2.29(m,2H),2.58(m,2H),3.60(m,1H),4.19(m,1H),4.46-4.55(m,1H),5.02(m,1H),5.46-5.62(m,2H),7.09(m,2H),7.16(m,1H),7.22-7.25(m,2H),7.34-7.45(m,6H),7.66(m,4H).
Embodiment 3
(Z)-7-((1R, 2R, 3R, 5S)-2-((S, E)-3-(tert-butyl diphenyl silica-5-benzene penta-1-alkene-1-yl)-3,5-dihydroxyl cyclopentyl) heptan-5-olefin(e) acid (5a)
Add 50 in 500 milliliters of there-necked flasks and digest compound 7(4-carboxylic butyl-triphenylphosphine bromide); 150 milliliters of anhydrous THF; add 25.5 gram potassium tert.-butoxides under the nitrogen protection in batches; stir after 30 minutes; be cooled to 0 to 10 degree; drip the solution of 14.5 gram 4a and 25 milliliters of THF; added in about 20 minutes; keeping 0 to 10 degree stirred 1 hour. rose to the room temperature restir naturally 10 to 20 hours. and most of solvent is removed in decompression; the 300 ml water solution dissolving that residuum is joined with 0.6 gram salt of wormwood, water layer is transferred PH=4-5 with 1N hydrochloric acid, adds 200 milliliters of MTBE; filter; with MTBE drip washing filter cake 2 times. the filtrate phase-splitting, merge organic phase, concentrate; obtain about 26 grams of 5a crude product, be directly used in next step.
Get concentrate in a small amount the back silica gel column chromatography (eluent is chloroform: methyl alcohol 40:1) obtain pure product.
1H-NMR(CDCl 3,300MHz)δ(ppm):1.06(s,9H),1.34(m,1H),1.62-2.27(m,11H),2.31(t,2H),2.61(t,2H),3.70(s,1H),4.09(s,1H),4.18(q,1H),5.07(dd,1H),5.32(m,2H),5.53(dd,1H),7.06(m,2H),7.14(m,1H),7.22(m,2H),7.33-7.43(m,6H),7.68(m,4H).
Embodiment 4
(Z)-7-((1R, 2R, 3R, 5S)-2-((S, E)-3-(tert-butyl diphenyl siloxy-5-benzene penta-1-alkene-1-yl)-3,5-dihydroxyl cyclopentyl)-N-ethyl heptan-5-alkene acid amides (6a)
25 gram 5a are dissolved in 300 milliliters of acetone, 0 degree drips 45 gram DBU, there is heat release .20 degree to stir after 1 hour slightly, be cooled to 0 degree again, drip 32 gram MeI, added in about 5 minutes, there are a large amount of white insolubless to separate out. stirring at room 15 hours. be concentrated into driedly, add as 300 mL of saline, extract waters with 600 milliliters of ethyl acetate gradation. merge organic phase, wash 2 times with 500 milliliters of 1N aqueous hydrochloric acids, 5% NaHCO3 washes 2 times, concentrates last silica gel, obtain about 10.2 gram (Z)-7-((1R with n-hexane/ethyl acetate (1:1) drip washing, 2R, 3R, 5S)-2-((S, E)-and 3-(tert-butyl diphenyl silica-5-benzene penta-1-alkene-1-yl)-3,5-dihydroxyl cyclopentyl) heptan-the yellow thick liquid of 5-olefin(e) acid methyl esters.
1H-NMR(CDCl 3,300MHz)δ(ppm):1.05(s,9H),1.34(m,1H),1.62-2.25(m,11H),2.29(t,2H),2.61(t,2H),3.63(s,3H),3.66(m,1H),4.09(m,1H),4.19(q,1H),5.04(dd,1H),5.34(m,2H),5.52(dd,1H),7.07(m,2H),7.14(m,1H),7.24(m,2H),7.33-7.44(m,6H),7.68(m,4H).
Ethylamine solution dissolving with 300 milliliter 70%, stirring at room 72 hours, TLC(product Rf=0.4, EtOAc/Hexane1:1) demonstration reacts completely. the most of solvent of pressure reducing and steaming, and residuum is transferred PH=5 with the NaHSO4 aqueous solution of 2N, with ethyl acetate extraction 4 times, merge organic phase, the NaHCO3 with 5% washes 2 times, concentrates to obtain semi-solid 6a, about 10 grams are directly used in next step.
1H-NMR(CDCl 3,300MHz)δ(ppm):1.07(s,9H),1.10(t,3H),1.35(m,1H),1.62-2.35(m,13H),2.60(t,2H),3.22(m,2H),3.75(s,1H),4.09(m,1H),4.20(q,1H),5.10(dd,1H),5.34(m,2H),5.55(dd,1H),5.88(s,1H),7.08(m,2H),7.15(m,1H),7.23(m,2H),7.35-7.45(m,6H),7.69(m,4H).
Embodiment 5
Bimatoprost (1a)
10 digest compound 6a dissolves with 100 milliliters of THF, adds 10 gram TBAF, and 50 degree stirred 4 hours, TLC (product Rf=0.2 EtOAc) detects no raw material. is poured onto in 250 milliliters of 1N aqueous hydrochloric acids, with 500 milliliters of ethyl acetate extraction, merge organic phase, wash salt washing, anhydrous sodium sulfate drying with 5% sodium bicarbonate aqueous solution, concentrate, obtain yellow semisolid, the white powder 4.5 that obtains 1a with ethyl acetate/normal hexane recrystallization restrains, six step total recoverys 60.8%.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.09(t,3H),136(m,1H),1.57-2.39(m,13H),2.60(m,2H),3.21(m,2H),3.92(t,1H),4.05-4.17(m,2H),5.31-5.64(m,4H),5.95(t,1H),7.18-7.30(m,5H)
Embodiment 6
(3aR, 4R, 5R, 6aS)-((R)-3-(tert-butyl diphenyl siloxy-5-benzene amyl group)-2-oxo six hydrogen-2H-pentamethylene is [b] furans-5-yl benzoic acid ester (3b) also for 4-
Add 10 in the 1L there-necked flask and digest compound 2b, 100 milliliters of methylene dichloride, 5 gram imidazoles; 0.25 gram DMAP is cooled to 0 degree under the nitrogen protection, drip the mixed solution of 10.1 gram TBDPSCl and 30 milliliters of methylene dichloride; added in about 10 minutes; the adularescent insolubles generates the .20 degree and stirred 16 hours, TLC(Rf=0.9, and toluene: EtOAc3:2) detection reaction is complete; with salt washing 2 times; anhydrous sodium sulfate drying filters the solution that obtains compound 3b, is directly used in later reaction.
Get concentrate in a small amount the back silica gel column chromatography (eluent is methylene dichloride: normal hexane 1:1) obtain pure product.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.06(s,9H),1.21(m,1H),1.34(m,1H),1.55(m,2H),1.72-1.88(m,3H),2.23-2.38(m,4H),2.60(m,2H),2.73(m,1H),3.84(s,1H),4.92(m,1H),5.08(m,1H),7.03(d,2H),7.15(m,1H),7.22(t,2H),7.34-7.42(m,8H),7.54(t,1H),7.65(m,4H),7.97(d,2H).
Embodiment 7
(3aR, 4R, 5R, 6aS)-((R)-3-(tert-butyl diphenyl siloxy-5-benzene amyl group) six hydrogen-2H-pentamethylene is [b] furans-2 also, 5-glycol (4b) for 4-
In the solution of embodiment 6, add 340 milliliters of methylene dichloride again; be cooled to-70 degree under the nitrogen protection; 150 milliliters of the DIBAL toluene solutions of dropping 25%; added in about 20 minutes. keep-70 degree and stirred 1.5 hours; slowly add 90 ml waters and destroy unnecessary DIBAL, remove by filter aluminium hydroxide, concentrated filtrate. with silica gel on the residue; column chromatography (methylene dichloride/methyl tertiary butyl ether 1:1) obtains compound 4b, 14.6g.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.03(s,9H),1.12-1.33(m,2H),1.51(m,2H),1.74-2.25(m,8H),2.59(m,2H),3.71(m,1H),3.80(m,1H),4.55(m,1H),5.44(m,1H),6.99(m,2H),7.13(m,1H),7.22(m,2H),7.34-7.45(m,6H),7.67(m,4H).
Embodiment 8
(Z)-7-((1R, 2R, 3R, 5S)-2-((R)-3-(tert-butyl diphenyl siloxy-5-benzene amyl group)-3,5-dihydroxyl cyclopentyl) heptan-5-olefin(e) acid (5b)
Add 60 in 500 milliliters of there-necked flasks and digest compound 7; 150 milliliters of anhydrous THF; add 30.5 gram potassium tert.-butoxides under the nitrogen protection in batches; stir after 30 minutes; 0 degree drips the solution of 14.5 gram 4b and 50 milliliters of THF, adds in about 10 minutes, keeps 0 degree and stirs 3 hours. and be poured onto 1.0 and restrain in the 400 ml water solution that salt of wormwood join; extract 2 times with 200 milliliters of MTBE; water layer is transferred PH=4, adds 300 milliliters of MTBE, filters; the filtrate phase-splitting; water extracts 2 times with 200 milliliters of MTBE again, merges organic phase, concentrates; obtain about 12.4 grams of 5b crude product, be directly used in next step.
Get concentrate in a small amount the back silica gel column chromatography (eluent is chloroform: methyl alcohol 40:1) obtain pure product.
1H-NMR(CDCl 3,300MHz)δ(ppm):1.05(s,9H),1.22-1.36(m,3H),1.49-1.83(m.9H),2.05-2.34(m,6H),2.55(m,2H),3.72-3.83(m,2H),4.09(s,1H),5.36(m,2H),7.01(d,2H),7.12(m,1H),7.20(m,2H),7.32-7.42(m,6H),7.67(m,4H).
Embodiment 9
(Z)-7-((1R, 2R, 3R, 5S)-2-((R)-3-(tert-butyl diphenyl siloxy-5-benzene amyl group)-3,5-dihydroxyl cyclopentyl) heptan-5-isopropyl gadoleate (6b)
12.4 gram 5b is dissolved in 190 milliliters of acetone, 0 degree drips 21 gram DBU, there is heat release .20 degree to stir after 1 hour slightly, be cooled to 0 degree again, drip 16.7 gram i-PrI, added in about 5 minutes, there are a large amount of white insolubless to separate out. stirring at room 15 hours. be concentrated into dried, add 300 mL of saline, extract water with 600 milliliters of ethyl acetate gradation. merge organic phase, wash 2 times with the 1N aqueous hydrochloric acid, 5% NaHCO3 washes 2 times, concentrate, last silica gel obtains about 7.1 grams of colourless viscous liquid 6b with n-hexane/ethyl acetate (1:1) drip washing. be directly used in next step.
1H-NMR(CDCl 3,300MHz)δ(ppm):1.07(s,9H),1.22(d,6H),1.22-1.38(m,3H),1.48-1.85(m.9H),2.05-2.32(m,6H),2.57(m,2H),3.75(s,1H),3.80(t,1H),4.11(s,1H),5.01(m,1H),5.37(m,2H),7.04(d,2H),7.14(m,1H),7.22(m,2H),7.34-7.44(m,6H),7.67(m,4H).
Embodiment 10
Latanoprost (1b)
Dissolve with 120 milliliters of THF 7.1 digest compound 6b, add 10 gram TBAF, 50 degree stirred 4 hours, TLC(product Rf=0.3, EtOAc) detect no raw material. be poured onto in 600 milliliters of 1N aqueous hydrochloric acids, with 500 milliliters of ethyl acetate extraction, merge organic phase, wash with 5% sodium bicarbonate aqueous solution, the salt washing, anhydrous sodium sulfate drying concentrates, last silica gel obtains about 4.2 grams, the five steps total recovery 39.6% of colourless viscous liquid 1b with n-hexane/ethyl acetate drip washing.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.23(d,6H),1.34(m,1H),1.40(m,1H),1.52(m,1H,),1.62(m,2H),1.65-173(m,3H),1.75-1.82(m,2H,),1.87(m,2H),2.13(m,2H),2.22(m,1H),2.28(t,2H),2.32(m,1H),2.68(m,1H),2.80(m,1H,),3.67(m,1H)3.95(m,1H,),4.18(m,1H),5.00(q,1H),5.40(dd,1H),5.46(dd,1H),7.18(m,1H,),7.21(m,2H,),7.29(m,2H,)
Embodiment 11
(3aR, 4R, 5R, 6aS)-4-((R, E)-3-(tert-butyl diphenyl siloxy-4-(3-4-trifluoromethylphenopendant) but-1-ene-1-yl)-2 oxo six hydrogen-2H-pentamethylene [b] furans-5-yl benzoic acid ester (3c) also
Add 10 in the 1L there-necked flask and digest compound 2c, 100 milliliters of methylene dichloride, 4.3 gram imidazoles, 0.25 gram DMAP is cooled to 0 degree under the nitrogen protection, drip the mixed solution of 8.6 gram TBDPSCl and 30 milliliters of methylene dichloride, adds in about 10 minutes.20 degree stirred 16 hours, and the TLC detection reaction is complete, and with salt washing 2 times, anhydrous sodium sulfate drying filters the solution that obtains compound 3c, is directly used in later reaction.
Get concentrate in a small amount the back silica gel column chromatography (eluent is methylene dichloride: normal hexane 1:1) obtain pure product.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.04(s,9H),2.13(s,1H),2.36-2.80(m,5H),3.81(m,1H),3.93(s,1H),4.52(q,1H),4.95(t,1H),5.11(q,1H),5.44(dd,1H),5.67(dd,1H),6.83(d,1H),6.92(s,1H),7.15(d,1H),7.29-7.42(m,9H),7.54(t,1H),7.66(m,4H),7.97(d,2H).
Embodiment 12
(3aR, 4R, 5R, 6aS)-4-((R, E)-3-(tert-butyl diphenyl siloxy-4-(3-4-trifluoromethylphenopendant) but-1-ene-1-yl) six hydrogen-2H-pentamethylene [b] furans-2 also, 5-glycol (4c)
In the solution of embodiment 11, add 340 milliliters of methylene dichloride again; be cooled to-70 degree under the nitrogen protection; 200 milliliters of the DIBAL toluene solutions of dropping 25%; added in about 20 minutes. keep-70 degree and stirred 2 hours; slowly add 110 ml waters and destroy unnecessary DIBAL, remove by filter aluminium hydroxide, concentrated filtrate. with silica gel on the residue; column chromatography (methylene dichloride/methyl tertiary butyl ether 1:1) obtains compound 4c, 14.1g.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.06(s,9H),1.39-2.35(m,6H),3.69(m,1H),3.88(m,1H),4.00(m,1H),4.51-4.58(m,2H),5.30(dd,1H),5.55-5.62(m,2H),6.89(m,1H),6.98(s,1H),7.16(d,1H),7.30-7.46(m,7H),7.69(d,4H).
Embodiment 13
(Z)-7-((1R, 2R, 3R, 5S)-2-((R, E)-3-(tert-butyl diphenyl siloxy-4-(3-4-trifluoromethylphenopendant) but-1-ene-1-yl)-3,5-dihydroxyl cyclopentyl) heptan-5-olefin(e) acid (5c)
Add 50 in 500 milliliters of there-necked flasks and digest compound 7; 150 milliliters of anhydrous THF; add 25.5 gram potassium tert.-butoxides under the nitrogen protection in batches; stir after 10-40 minute; 0 degree drips the solution of 14.1 gram 4c and 40 milliliters of THF; added in about 20 minutes; keeping the 0-10 degree stirred 3 hours. and be poured onto in the 400 ml water solution that 1.0 gram salt of wormwood join, extract 2 times with 200 milliliters of MTBE, water layer is with 1N hydrochloric acid accent PH=4-5; add 300 milliliters of MTBE; filter, the filtrate phase-splitting, organic phase concentrates; obtain about 11.2 grams of 5c crude product, be directly used in next step.
Get concentrate in a small amount the back silica gel column chromatography (eluent is chloroform: methyl alcohol 40:1) obtain pure product.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.06(s,9H),1.38(m,1H),1.63-1.77(m,3H),1.95-2.33(m,8H),3.76(m,1H),3.86(m,1H),3.98(m,1H),4.10(m,1H),4.53(m,1H),5.33(m,3H),5.60(dd,1H),6.89(m,1H),6.95(s,1H),7.15(d,1H),7.30-7.43(m,7H),7.7(d,4H).
Embodiment 14
(Z)-7-((1R, 2R, 3R, 5S)-2-((R, E)-3-(tert-butyl diphenyl siloxy-4-(3-4-trifluoromethylphenopendant) but-1-ene-1-yl)-3,5-dihydroxyl cyclopentyl) heptan-5-isopropyl gadoleate (6c)
11.2 gram 5c is dissolved in 160 milliliters of acetone, 0 degree drips 19 gram DBU, there is heat release .20 degree to stir after 1 hour slightly, be cooled to 0 degree again, drip 15.6 gram i-PrI, added in about 5 minutes, there are a large amount of white insolubless to separate out. stirring at room 15 hours. be concentrated into dried, add as 300 mL of saline, extract water with 600 milliliters of ethyl acetate gradation. merge organic phase, wash 2 times with 500 milliliters of 1N aqueous hydrochloric acids, 5% NaHCO3 washes 2 times, concentrate, last silica gel obtains about 7.4 grams of colourless viscous liquid 6c with n-hexane/ethyl acetate drip washing. be directly used in next step.
1H-NMR(CDCl 3,300MHz)δ(ppm)1.06(s,9H),1.20(d,6H),1.38(m,1H),1.63-1.76(m,3H),1.95-2.26(m,8H),3.75(m,1H),3.86(m,1H),3.99(m,1H),4.13(m,1H),4.53(m,1H),4.99(m,1H),5.34(m,3H),5.59(dd,1H),6.87(m,1H),6.96(s,1H),7.15(d,1H),7.31-7.45(m,7H),7.7(m,4H).
Embodiment 15
Travoprost (1c)
Dissolve with 120 milliliters of THF 7.4 digest compound 6c, add 10 gram TBAF, 50 degree stirred 4 hours, TLC(product Rf=0.4, EtOAc) detect no raw material. be poured onto in 600 milliliters of 1N aqueous hydrochloric acids, with 500 milliliters of ethyl acetate extraction, merge organic phase, wash with 5% sodium bicarbonate aqueous solution, the salt washing, anhydrous sodium sulfate drying concentrates, last silica gel obtains about 4.5 grams, the five steps total recovery 42.8% of colourless viscous liquid 1c with n-hexane/ethyl acetate drip washing.
1H-NMR(CDCl 3,300MHz)δ(ppm)δ1.22(d,6H),1.40(m,1H),1.66(t,2H),1.81(dd,1H),2.08(m,4H),2.26(m,4H),2.53(bs,1H),3.13(bs,2H),3.99(m,3H),4.19(t,1H),4.55(m,1H),5.00(m,1H),5.39(m,2H),5.71(m,2H),7.15-7.25(m,3H),7.39(t,1H).

Claims (16)

1. the preparation method who prepares the plain analogue in following formula 1 prostatitis,
Figure FDA00003152887500011
Wherein
A:X=-CH 2-, Z=-H is two keys between 13,14;
B:X=-CH 2-, Z=-H is singly-bound between 13,14;
C:X=-O-, Z=-CF 3, be two keys between 13,14;
Described method comprises:
(a) under alkaline condition, use hydroxyl protecting group, only 15 hydroxyls of formula 2 compounds are protected;
(b) DIBAL reduction lactone ketone group, acquisition formula 4 intermediates,
(c) use 4-carboxylic butyl-triphenylphosphine bromide and formula 4 intermediates to carry out the Wittig reaction, behind the connection α chain, esterification or amidation;
(d) slough 15-position hydroxyl protecting group, obtain the plain analogue in prostatitis of formula 1.
2. the method for claim 1 is hydroxyl protecting group with tert-butyl diphenyl silicon ether (TBDPS) wherein, only 15 hydroxyls is protected; after connecting the α chain; do esterification or amidation earlier, slough silicon ether protecting group by tetrabutyl ammonium fluoride at last, obtain prostaglandin(PG).
3. method as claimed in claim 2 can be selected alkane and various ethers, alkane, aromatics equal solvent for use during wherein with 15 hydroxyls of tert-butyl diphenyl silicon ether protection.
4. method as claimed in claim 3 wherein can be selected methylene dichloride for use, THF, and MCPE, DMF, toluene are as the solvent of step (a), and alkali can be selected imidazoles, triethylamine, pyridine, DMAP, DEA for use.
5. as the arbitrary described method of claim 1-3, wherein temperature of reaction control is at-10～60 degree, and the reaction times was at 1～20 hour.
6. the method for claim 1, wherein DIBAL reduction solvent can be selected ethers, THF, toluene, haloalkane for use. and temperature of reaction-80～-10 degree, the reaction times was at 1～20 hour.
7. method as claimed in claim 1 or 2, wherein the Wittig reaction can be used systems such as DMSO/NaH, t-BuOK/THF, NaHMDS/THF.
8. the method for claim 1, wherein the control of the temperature of reaction of step (c) is at-50～50 degree. 1～20 hour reaction times.
9. as claim 1 or 9 described methods, wherein esterification can be used diazomethane, or methyl-sulfate, methylating reagent and DBU such as methyl iodide, and pyridine, triethylamine, DME etc. are rich, and use is united in sour agent; The i-PrI/DBU system is generally used in the isopropyl esterification.
10. use pure ethamine or its water/alcoholic solution as the method as claimed in claim 1 or 2, aminolysis step 1, temperature of reaction-20～50 degree, 4 hours～4 days reaction times.
11. method as claimed in claim 1 or 2, deprotection steps are generally used tetrabutyl fluoride amine or hydrofluoric acid or other silicon ethers deprotecting regent; Solvent can be selected ethers for use, THF, ester class, haloalkane and aromatic solvents.
12. method as claimed in claim 11, the temperature of reaction of deprotection are-10～70 degree, the reaction times was at 1～20 hour.
13. formula 3 compounds:
Figure FDA00003152887500021
Wherein
A:X=-CH 2-, Z=-H is two keys between carbon 13 and the carbon 14
B:X=-CH 2-, Z=-H is singly-bound between carbon 13 and the carbon 14
C:X=-O-, Z=-CF 3, be two keys between carbon 13 and the carbon 14.
14. separate the intermediate that obtains in the method for claim 1, formula 4 compounds:
Figure FDA00003152887500022
Wherein
A:X=-CH 2-, Z=-H is two keys between carbon 13 and the carbon 14
B:X=-CH 2-, Z=-H is singly-bound between carbon 13 and the carbon 14
C:X=-O-, Z=-CF 3, be two keys between carbon 13 and the carbon 14.
15. separate the intermediate that obtains in the method for claim 1, formula 5 compounds:
Figure FDA00003152887500023
Wherein
A:X=-CH 2-, Z=-H is two keys between carbon 13 and the carbon 14
B:X=-CH 2-, Z=-H is singly-bound between carbon 13 and the carbon 14
C:X=-O-, Z=-CF 3, be two keys between carbon 13 and the carbon 14.
16. separate the intermediate that obtains in the method for claim 1, formula 6 compounds:
Figure FDA00003152887500024
Wherein
A:X=-CH 2-, Z=-H is two keys between carbon 13 and the carbon 14, W=-CH3, or-NHEt
B:X=-CH 2-, Z=-H is singly-bound between carbon 13 and the carbon 14, W=-i-Pr
C:X=-O-, Z=-CF 3, be two keys between carbon 13 and the carbon 14, W=-i-Pr.
CN2013101650750A 2013-05-07 2013-05-07 Novel method for synthetizing prostaglandin analogue Pending CN103288698A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2013101650750A CN103288698A (en) 2013-05-07 2013-05-07 Novel method for synthetizing prostaglandin analogue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013101650750A CN103288698A (en) 2013-05-07 2013-05-07 Novel method for synthetizing prostaglandin analogue

Publications (1)

Publication Number Publication Date
CN103288698A true CN103288698A (en) 2013-09-11

Family

ID=49090298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013101650750A Pending CN103288698A (en) 2013-05-07 2013-05-07 Novel method for synthetizing prostaglandin analogue

Country Status (1)

Country Link
CN (1) CN103288698A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084074A (en) * 2017-12-25 2018-05-29 厦门欧瑞捷生物科技有限公司 A kind of method of simple and effective synthesis dinoprost
CN111757868A (en) * 2018-02-21 2020-10-09 尼科斯股份有限公司 Nitric oxide donating prostaglandin analogs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1774417A (en) * 2001-05-31 2006-05-17 梵泰克实验室有限公司 A new process for the preparation of 17-phenyl-18, 19, 20-trinor-PGF2A and its derivatives
CN101003504A (en) * 2006-01-18 2007-07-25 佳和桂科技股份有限公司 Processes and intermediates for the preparations of prostaglandins
US20110288179A1 (en) * 2006-08-29 2011-11-24 Arie Gutman Bimatoprost crystalline form i
WO2012011128A1 (en) * 2010-07-23 2012-01-26 Aptuit Laurus Private Limited Preparation of prostaglandin derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1774417A (en) * 2001-05-31 2006-05-17 梵泰克实验室有限公司 A new process for the preparation of 17-phenyl-18, 19, 20-trinor-PGF2A and its derivatives
CN101003504A (en) * 2006-01-18 2007-07-25 佳和桂科技股份有限公司 Processes and intermediates for the preparations of prostaglandins
US20110288179A1 (en) * 2006-08-29 2011-11-24 Arie Gutman Bimatoprost crystalline form i
WO2012011128A1 (en) * 2010-07-23 2012-01-26 Aptuit Laurus Private Limited Preparation of prostaglandin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陆国元: "《有机反应与有机合成》", 30 June 2009, 科学出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084074A (en) * 2017-12-25 2018-05-29 厦门欧瑞捷生物科技有限公司 A kind of method of simple and effective synthesis dinoprost
CN108084074B (en) * 2017-12-25 2018-11-20 厦门欧瑞捷生物科技有限公司 A kind of method of simple and effective synthesis dinoprost
CN111757868A (en) * 2018-02-21 2020-10-09 尼科斯股份有限公司 Nitric oxide donating prostaglandin analogs
CN111757868B (en) * 2018-02-21 2023-03-14 尼科斯股份有限公司 Nitric oxide donating prostaglandin analogs

Similar Documents

Publication Publication Date Title
US4131738A (en) 6-Hydroxy-PGE1 compounds
KR101634818B1 (en) Process for the preparation of prostaglandin analogues and intermediates thereof
EP2495235B1 (en) Process for the synthesis of prostaglandins and intermediates thereof
EP2135860A1 (en) Improved process for the production of bimatoprost
US6689901B2 (en) Process and intermediates to prepare latanoprost
US10501410B2 (en) Pocess for the preparation of high purity prostaglandins
WO2011055377A1 (en) A novel process for the preparation of prostaglandins and intermediates thereof
US20100010239A1 (en) Process for the Production of Prostaglandins and Prostaglandin Analogs
US4098805A (en) 9-deoxy-9-methylene-pgf-type amides
CN103288698A (en) Novel method for synthetizing prostaglandin analogue
WO2011095990A2 (en) Process for the purification of prostaglandins and analogues thereof
US20100041912A1 (en) Method for the wittig reaction in the preparation of carboprost
JP2003531824A (en) Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in treating glaucoma and ocular hypertension
AU2001233286A1 (en) Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
US4118584A (en) 9-Deoxy-9-methylene-16-phenyl-PGF compounds
WO2014083367A1 (en) Process for the preparation of travoprost
JPS6072859A (en) 16-fluoro-16,17-didehydroprostanoids and manufacture
CA1038378A (en) 13-cis prostaglandin derivatives and methods of making
Tanase et al. New 9β-halogenated Prostaglandine Analogues with an Ester Group at C-6 of the α-side Chain
US20030187071A1 (en) Process and intermediates to prepare latanoprost
US4046801A (en) 13-Cis prostaglandin derivatives
DE102006025695A1 (en) Selective enzymatic esterification and solvolysis of an epimeric vitamin D analog and separation and epimerization of the epimers
US4005106A (en) 3β-[(Methoxalyl)oxy]-2α-(3-oxo-1-octenyl)-5-oxo-1β-cyclopentaneheptanoic acid and process
DE2830100A1 (en) NEW PROSTAGLANDIN ANALOGS
JP2011521666A (en) Prostaglandin F2α ester production method using lipase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130911